腺癌,与HPV无关,由子宫颈引起的中肾型(以下称为“中肾癌”)很少见,它的待遇尚未确定,其对化疗的敏感性尚未得到充分研究。在这里,我们报告了一名30岁的女性患者,该患者在我们医院就诊,主要主诉生殖器异常出血。我们怀疑宫颈癌。根据检查,活检,和成像,她被诊断为宫颈IIA2期腺癌,并计划进行手术治疗.因为她感染了SARS-COV-2,她接受了两个疗程的紫杉醇-卡铂(TC)治疗,根据目前SARS-COV-2感染后的手术风险评估,等待至少8周。患者被认为有部分反应,并接受紫杉醇和卡铂治疗,之后,她被认为有部分反应,并接受了全子宫切除术。诊断为IIA2期间肾癌,ypT1b2N0M0是在切除标本的组织病理学检查后制成的。患者在手术后接受了4个额外疗程的TC治疗,并且在13个月内没有复发。我们报告了第一例宫颈癌患者对TC方案新辅助化疗的反应。
Adenocarcinoma, HPV-independent, mesonephric type (hereafter referred to as \"mesonephric carcinoma\") arising from the cervix is rare, its treatment has not been established, and its sensitivity to chemotherapy has not been fully investigated. Here we report on a 30-year-old female patient who presented at our hospital with a chief complaint of abnormal genital bleeding. We suspected cervical cancer. Based on examination, biopsy, and imaging, she was diagnosed with stage IIA2 adenocarcinoma of the cervix and was scheduled for surgery. Because she had a SARS-COV-2 infection, she was given two courses of paclitaxel-
carboplatin (TC) therapy, based on the then-current surgical risk assessment after SARS-COV-2 infection, with a waiting period of at least 8 weeks. The patient was deemed to have a partial response and was treated with paclitaxel and
carboplatin, after which she was deemed to have a partial response and underwent total hysterectomy. A diagnosis of stage IIA2 mesonephric carcinoma, ypT1b2N0M0, was made after histopathologic examination of an excised specimen. The patient was treated with 4 additional courses of TC therapy after surgery, and has had no recurrence in 13 months. We report a first
case of response to neoadjuvant chemotherapy with TC regimen in a patient with mesonephric carcinoma of the cervix.